AXNX - Axonics Modulation Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
30.25
-0.34 (-1.11%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close30.59
Open29.87
Bid0.00 x 1200
Ask0.00 x 1000
Day's Range29.77 - 31.02
52 Week Range14.00 - 43.37
Volume327,904
Avg. Volume726,756
Market Cap1.027B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.59
Earnings DateMar 03, 2020 - Mar 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.38
  • Insiders Roundup: Uber, AutoNation
    GuruFocus.com

    Insiders Roundup: Uber, AutoNation

    Largest insider trades of the week Continue reading...

  • Business Wire

    Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer

    Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (SNM) devices for the treatment of bladder and bowel dysfunction, today announced U.S. Food & Drug Administration ("FDA") approval of an enhanced, second-generation Programmer for its r-SNM® System under a premarket approval ("PMA") application supplement.

  • Market Sentiment Around Loss-Making Axonics Modulation Technologies, Inc. (NASDAQ:AXNX)
    Simply Wall St.

    Market Sentiment Around Loss-Making Axonics Modulation Technologies, Inc. (NASDAQ:AXNX)

    Axonics Modulation Technologies, Inc.'s (NASDAQ:AXNX): Axonics Modulation Technologies, Inc., a medical technology...

  • Business Wire

    Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited revenue of approximately $10 million for the fourth quarter of 2019 as compared to $0.5 million in the prior year period. For the full year ended December 31, 2019, unaudited revenue was approximately $14 million as compared to $0.7 million for all of 2018.

  • Is Axonics Modulation Technologies, Inc. (AXNX) A Good Stock To Buy?
    Insider Monkey

    Is Axonics Modulation Technologies, Inc. (AXNX) A Good Stock To Buy?

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

  • Business Wire

    Axonics® Granted Six U.S. Patents and Allowed Three Additional Patents Related to its Implantable Sacral Neuromodulation Technology

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced that the United States Patent and Trademark Office has issued or allowed Axonics nine U.S. utility patents in 2019, along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

  • Business Wire

    Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), ("Axonics"), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced that the underwriters of its follow-on public offering exercised in full their option to purchase an additional 750,000 shares of common stock from Axonics at the offering price of $22.00 per share, less underwriting discounts and commissions.

  • Business Wire

    Axonics® Provides Survey Results from Physician Seminar Series Showcasing the Recently FDA Approved Axonics r-SNM® System

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced completion of a post-approval U.S. physician seminar series and the results of surveys collected from the attendees. Axonics sponsored five one-day Saturday seminars held over the past two months in Orlando, Irvine, Dallas, Boston and Atlanta.

  • Business Wire

    Health Canada Approves Full-Body MRI Labeling for the Axonics® Sacral Neuromodulation System

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“r-SNM®”) devices for the treatment of bladder and bowel dysfunction, today announced Health Canada (Homologation d'un instrument medical) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 and 3 Tesla MRI scanners for patients implanted with the Axonics r-SNM System. Axonics previously received Health Canada approval for its complete r-SNM System and related system components in January 2017 and has been marketing in Canada since 2018. The U.S. Food & Drug Administration approved the Axonics r-SNM System for full-body MRI scans for 1.5 Tesla MRI scans in September 2019.

  • TEST Business Wire Releases

    Axonics® to Present at Upcoming Investor Conferences

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:

  • Business Wire

    Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that surgeons have begun implanting commercial patients with the Axonics r-SNM® System at Sanford Health facilities (“Sanford”). Sanford Health, headquartered in Sioux Falls, South Dakota, is one of the largest rural health systems in the United States, with 44 hospitals and 1,400 physicians in 26 states and nine countries. Axonics and Sanford have a formal agreement permitting commercial sale of the Axonics r-SNM System into Sanford facilities.

  • Business Wire

    Axonics® Announces Closing of $110 Million Public Offering of Common Stock

    Wells Fargo Securities acted as lead manager for the offering. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained by contacting: BofA Securities, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or Barclays, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by e-mail at Barclaysprospectus@broadridge.com.

  • Business Wire

    Axonics® Announces Agreement to Supply its Sacral Neuromodulation System to The University of Tennessee Medical Center

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has entered into an agreement to supply the Axonics r-SNM® System to The University of Tennessee Medical Center (UTMC) in Knoxville, Tennessee.

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • Business Wire

    Axonics® Announces Pricing of Public Offering of Common Stock

    The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $101 million. The offering is expected to close on November 22, 2019, subject to the satisfaction of customary closing conditions. Axonics anticipates using net proceeds from the offering, together with its existing cash, cash equivalents and short-term and long-term investments, to support the commercial launch of its r-SNM® System in the United States, Europe and Canada; to conduct SNM-related research and development activities and to fund the technological enhancement of its r-SNM System; and for working capital and general corporate purposes.

  • Business Wire

    Axonics® Announces Proposed Public Offering of Common Stock

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $110,000,000 in shares of its common stock. The offering is expected to consist of $100,000,000 of shares to be offered by Axonics and $10,000,000 of shares to be offered by selling stockholders. Axonics expects to grant the underwriters a 30-day option to purchase up to $16,500,000 in additional shares of its common stock at the public offering price, less the underwriting discount.

  • Axonics Modulation Technologies, Inc. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
    Simply Wall St.

    Axonics Modulation Technologies, Inc. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

    It's been a pretty great week for Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) shareholders, with its shares...

  • Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates

    Axonics (AXNX) delivered earnings and revenue surprises of -21.92% and -9.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Axonics® Announces Third Quarter 2019 Financial Results and Operational Update

    Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, reported today financial results for the third quarter ended September 30, 2019, and provided an update on operational initiatives.

  • Business Wire

    Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration (“FDA”) for the clinical indications of overactive bladder (“OAB”) and urinary retention. The FDA premarket approval (“PMA”) grants Axonics the right to market its product in the United States for the clinical indications of OAB (urinary urge incontinence and urinary urge frequency) as well as urinary retention, representing the largest segment of the market for SNM devices.

  • Business Wire

    Axonics® to Report 2019 Third Quarter and Nine-Month Financial Results and Host a Conference Call on November 14

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today announced that it will release financial results for the third quarter and first nine months of 2019, and provide an update on U.S. launch activities after the market closes on Thursday, November 14, 2019. In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and current business developments. Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 4373989.

  • Business Wire

    Axonics® Responds to Patent Action by Medtronic

    Axonics Modulation Technologies, Inc. (AXNX), a medical technology company that has developed and is commercializing sacral neuromodulation (“SNM”) devices, today announced that it received notice on Monday, November 4, that Medtronic, Inc, Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and its U.S. operating company Medtronic USA, Inc. (“Medtronic”) filed a lawsuit against Axonics in the United States District Court for the Central District of California. The lawsuit asserts that the Axonics r-SNM® System infringes Medtronic’s U.S. Patent Nos.

  • Analysts Bullish on Axonics' Prospects
    GuruFocus.com

    Analysts Bullish on Axonics' Prospects

    Rated a buy with target set 40% above current stock price Continue reading...

  • Have Insiders Been Selling Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Shares?
    Simply Wall St.

    Have Insiders Been Selling Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...